Long-term follow-up of survivors of childhood cancer (SIGN Clinical Guideline 132)

Hoong-Wei Gan,1,2 Helen A Spoudeas2,3

BACKGROUND
Five-year childhood cancer survival rates have increased to 80–90% for some tumours due to intensified treatments and better supportive care imposed on an incidence stable over four decades.1 2 Between 2005 and 2012, the number of UK survivors has risen from 26 000 to 33 000, or from 1:1000 to 1:715 UK adults.3 4 However, 40% experience chronic severe or life-threatening consequences (late effects) of their tumour and/or its treatment.5 The recent National Cancer Survivorship Initiative (NCSI) has highlighted the unmet need in service provision for adult childhood cancer survivors, with a proposed survivorship framework and stratified care pathways modelled on >20 years’ prior experience.6 7

In March 2013, the Scottish Intercollegiate Guidelines Network (SIGN) published updated guidance on long-term follow-up of childhood cancer survivors to aid the ‘identification, assessment and management of late effects’ aimed at primary, secondary and tertiary healthcare practitioners.8 The Guideline Development Group (GDG) included representatives from paediatric haematology, oncology, endocrinology, reproductive medicine, cardiology, general paediatrics and general practice, as well as a survivor.

PREVIOUS AND OTHER ASSOCIATED GUIDELINES
The previous SIGN 76 guideline was published in 2004. This revision updates information on fertility preservation, cardiac late effects and patient information provision, and provides new sections on subsequent primary cancers (SPCs), bone health and metabolic syndrome. The UK Children’s Cancer Study Group’s (UK CCSG) best practice statement9 is a potentially valuable companion guideline for tertiary care practitioners requiring details of therapeutic regimens and their toxicity profiles to individualise care for those most affected.

KEY ISSUES

▸ Section 11: long-term follow-up provides a useful summary of the recommendations. It recognises the multisystemic and evolving nature of late effects over decades of survival, concluding a need for lifelong multidisciplinary follow-up (table 1). The authors suggest a three-tiered follow-up stratified by disease-related and/or treatment-related morbidity risk (table 2) and list the key multidisciplinary professionals required (box 1).

▸ Subsequent primary cancers (SPCs)—The British Childhood Cancer Survivor Study10 and others have shown an excess SPC risk—>50% due to gastrointestinal, genitourinary, breast and lung cancers—persisting into old age.

▸ Fertility—The impact of cancer treatment on the pituitary–gonadal axis, reproductive capacity and options for pretreatment fertility preservation are complex and differ between the sexes (see British Fertility Society review for a fuller discussion11). In boys, post-treatment sub/infertility may exist despite a normal puberty and potency.12 With intracytoplasmic sperm injection, oligospermia is no barrier to fertility preservation, while long-term spermatogenic recovery is possible.13 By contrast, pubertal delay or secondary amenorrhoea may herald sub/infertility in girls whose options are more limited. Pretreatment gonadotropin-releasing hormone analogues, ovarian transposition and oocyte collection are unproven and/or impracticable. Prepubertal children of either sex have no recommended options outside a clinical trial. Miscarriage rates are increased, but
| Late effect | High-risk factors | Specific late effects | Screening methods/ management |
|------------|------------------|-----------------------|------------------------------|
| Subsequent primary cancers (SPCs) | Genetic predisposition, eg, NF-1 Radiotherapy | Dependent on syndrome Delayed presentation >5 years from treatment, at edge of radiation field (eg, mediastinal radiotherapy and breast SPCs) Chemotherapy* (alkylating agents, epipodophyllotoxins) | As per guidance for specific syndromes No consensus Promote healthy lifestyle behaviours |
| Sub-/infertility | Both sexes | Cranial radiotherapy Pelvic radiotherapy Boys Chemotherapy* (alkylating agents) Gonadal radiotherapy/ total body irradiation (TBI) Girls Chemotherapy* (alkylating agents) Abdominopelvic radiotherapy | Hypogonadotropic hypogonadism (pubertal arrest/ delay) Sexual dysfunction Azoospermia Azoospermia Hypergonadotropic hypogonadism (less likely—pubertal arrest/ delay, sexual dysfunction) Hypergonadotropic hypogonadism (pubertal arrest/ delay/ oligoamenorrhoea) Uterine dysfunction (premature delivery, low birth weight) | See individual sections for assessment depending on sex Consider psychological referral Semen analysis±cryopreservation, FSH, inhibin B Semen analysis±cryopreservation, FSH, inhibin B Regular pubertal assessment, LH, testosterone ±pubertal induction/ testosterone supplementation Regular pubertal assessment, FSH, AMH ±pubertal induction/ female hormone replacement therapy ±oocyte cryopreservation if postpubertal |
| Cardiac effects | Chemotherapy (anthracyclines) Cardiac/mediastinal radiotherapy | Congestive heart failure Cardiovascular (especially coronary artery) disease | Echocardiography: Fractional shortening (FS) and ejection fraction (EF) measurements 2–3 yearly if anthracycline dose >250 mg/m² 5 yearly if anthracycline dose <250 mg/m² Treat as per regular heart failure/cardiovascular disease guidelines Promote healthy lifestyle behaviours |
| Bone health | Chemotherapy (glucocorticoids, high dose methotrexate, 6-mercaptopurine) Cranial radiotherapy Bone marrow transplantation Endocrine dysfunction (GH deficiency, hypogonadism, hypothyroidism) | Osteoporosis (osteonecrosis with glucocorticoids) | Dual energy X-ray absorptiometry (DXA)/ peripheral quantitative CT/ quantitative ultrasound: BMD or bone mineral content (BMC) Z-scores adjusted for age, sex and height 2 years post-end of treatment Serial measurements not required unless abnormal or clinical change Sex steroid replacement Promote healthy lifestyle behaviours |
| Metabolic syndrome | ALL (especially after bone marrow transplantation) Brain tumours (especially after cranial radiotherapy and growth hormone deficiency) | Obesity Dyslipidaemia Insulin resistance Cardiovascular disease | BP and BMI: Annually in all survivors Fasting glucose, insulin, lipid profile: 2 yearly if obese/ overweight 5 yearly if normal weight Treat as per regular obesity guidelines |
| Cognitive outcomes | | Cranial radiotherapy | Cognitive decline Psychosocial dysfunction | Neuropsychological assessment: Pretreatment and then annually |

---

Gan H-W, et al. Arch Dis Child Educ Pract Ed 2014;99:138–143. doi:10.1136/archdischild-2013-305452

Copyright.
there is no excess of congenital or genetic disorders in offspring.

- **Cardiac effects**—Anthracycline-induced heart failure and mediastinal irradiation-induced cardiovascular disease may take years to manifest and may be additive. There is limited evidence for prophylactic ACE inhibitors or β-blockers, hence standard heart failure management is recommended.

- **Bone health**—Bone mineral density (BMD) as measured by DEXA is age-dependent, sex-dependent, puberty-dependent and height-dependent, thus Z-scores rather than T-scores need cautious interpretation. The only evidence-based treatment for osteopenia is sex steroid replacement, although its effect on fracture risk is unknown.

- **Metabolic syndrome**—Studies are limited to acute lymphoblastic leukaemia (ALL) and brain tumour survivors. A normal body mass index (BMI) does not preclude insulin resistance and dyslipidaemia. Annual blood pressure and BMI assessments are recommended.

- **Cognitive/psychosocial issues**—Cranial irradiation-induced cognitive decline is age-dependent, sex-dependent and dose-dependent and compounded by adjuvant chemotherapy. All survivors are at increased risk of psychosocial maladjustment and warrant consideration for extra educational support.

- **Growth**—All new cancer patients require accurate auxology at diagnosis and regularly thereafter to adult height, although the feasibility of performing this means that low-risk patients will need monitoring in primary or secondary care. Growth velocity requires interpreting in light of puberty and hormone replacement. Growth hormone (GH) replacement—important for bone mineralisation and childhood growth—does not increase cancer recurrence and should be substituted early particularly after spinal irradiation as it cannot fully reverse the detriment on adult height.

- **Thyroid dysfunction**—Low-dose irradiation scatter can cause compensated and frank primary hypothyroidism years after treatment. Secondary hypothyroidism (thyroid-stimulating hormone deficiency) attributed to cranial irradiation is, in our experience, unusual outside the context of suprasellar tumours. Lifelong monitoring is recommended alongside education on self-examination.

- **Information provision**—Information on healthy lifestyle, support networks and the importance of long-term follow-up should be given to all survivors.

**UNDERLYING EVIDENCE BASE**

These SIGN guidelines represent a synthesis of systematic reviews summarising the best available evidence in accordance with standardised methodology. Unlike the National Institute for Health and Care Excellence (NICE), SIGN does not require a mandatory cost-effectiveness analysis. Recommendations graded A–D are based on

---

**Table 1 Continued**

| Late effect | High-risk factors | Screening methods/management |
|-------------|------------------|-----------------------------|
| Growth      | Craniopharyngiomas (and other hypothalapitary tumours) | Pituitary function testing at diagnosis and regularly thereafter |
| Thyroid dysfunction | Neck, (cranio) spinal | Thyroid function tests: At end of treatment and then annually |
| Thyroid dysfunction | (cranio) spinal and total body | Thyroid hormone replacement |
| Thyroid dysfunction | Irradiation | Thyroid cancer |
| Thyroid dysfunction | Chemotherapy | Secondary theray hypothyroidism |
| Thyroid dysfunction | Chemotherapy | Tertiary mechanism |

*Clinicians should note that all chemotherapy may be associated with an increased risk of SPCs and sub-fertility.*

---

**Table 1**

| Late effect | Specific late effects | Evidence level/grade |
|-------------|----------------------|----------------------|
| Growth      | Growth hormone deficiency | 2+/B-C |
| Growth      | Pubertal delay/arrest | 2+/B-C |
| Growth      | Other pituitary hormone deficiencies | 2+/B-C |
| Thyroid dysfunction | Primary hypothyroidism | 2+/B-C |
| Thyroid dysfunction | Thyroid nodules | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid function tests: At end of treatment and then annually | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid function tests: At end of treatment and then annually | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |

---

**Table 1 Continued**

| Late effect | Specific late effects | Evidence level/grade |
|-------------|----------------------|----------------------|
| Growth      | Growth hormone deficiency | 2+/B-C |
| Growth      | Pubertal delay/arrest | 2+/B-C |
| Growth      | Other pituitary hormone deficiencies | 2+/B-C |
| Thyroid dysfunction | Primary hypothyroidism | 2+/B-C |
| Thyroid dysfunction | Thyroid nodules | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid function tests: At end of treatment and then annually | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |

---

**Table 1 Continued**

| Late effect | Specific late effects | Evidence level/grade |
|-------------|----------------------|----------------------|
| Growth      | Growth hormone deficiency | 2+/B-C |
| Growth      | Pubertal delay/arrest | 2+/B-C |
| Growth      | Other pituitary hormone deficiencies | 2+/B-C |
| Thyroid dysfunction | Primary hypothyroidism | 2+/B-C |
| Thyroid dysfunction | Thyroid nodules | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid function tests: At end of treatment and then annually | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |

---

**Table 1 Continued**

| Late effect | Specific late effects | Evidence level/grade |
|-------------|----------------------|----------------------|
| Growth      | Growth hormone deficiency | 2+/B-C |
| Growth      | Pubertal delay/arrest | 2+/B-C |
| Growth      | Other pituitary hormone deficiencies | 2+/B-C |
| Thyroid dysfunction | Primary hypothyroidism | 2+/B-C |
| Thyroid dysfunction | Thyroid nodules | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
| Thyroid dysfunction | Thyroid function tests: At end of treatment and then annually | 2+/B-C |
| Thyroid dysfunction | Thyroid hormone replacement | 2+/B-C |
| Thyroid dysfunction | Thyroid cancer | 2+/B-C |
Table 2  Suggested risk stratification of levels of follow-up for 5-year childhood cancer survivors after completion of treatment (reproduced from SIGN 132: Long term follow up of survivors of childhood cancer by kind permission)8

| Level | Treatment | Follow-up | Frequency | Examples |
|-------|-----------|-----------|-----------|----------|
| 1     | Surgery alone | Postal/telephone | 1–2 yearly | Survivors of Wilms’ tumour stage, I/II Langerhans cell histiocytosis (single system disease), Germ cell tumours (surgery only) |
|       | Low-risk chemotherapy | | | |
| 2     | Chemotherapy | Nurse/primary care-led | 1–2 yearly | Majority of survivors |
|       | Cranial radiotherapy ≤24 Gy | | | |
| 3     | Any other radiotherapy (cranial radiotherapy >24 Gy) | Medically supervised long-term follow-up clinic | Annually | Survivors of any brain tumour, Bone marrow transplantation, Stage 4 patients of any tumour type |
|       | Megatherapy (ie, high-dose chemotherapy) | | | |

SIGN, Scottish Intercollegiate Guidelines Network.

Hierarchy of evidence from level 1 (meta-analyses, systematic reviews or randomised controlled trials) to level 4 (expert opinion).

HOW DO I IMPLEMENT THESE GUIDELINES IN MY PRACTICE?
- Primary care practitioners need to be alert to the many late organ toxicities incurred by increasing treatment intensity that may manifest decades after treatment. Lifelong surveillance for endocrinopathies, subfertility, SPCs, cardiovascular disease, obesity and metabolic syndrome particularly in low-risk patients can only realistically occur in primary care, alongside supporting healthy lifestyle behaviours (including monitoring vitamin D status) and participation in secondary/tertiary follow-up. Young adult survivors may seek support for psychological illness or subfertility.
- Secondary care practitioners will monitor growth, puberty, thyroid function and neurocognitive development until adulthood, with appropriate specialist referral. Letters of support may be required for missed school attendances, statementing and disability living allowance applications. Adult physicians will be responsible for lifelong monitoring of cardiovascular disease, obesity, thyroid function, bone and sexual health, fertility and SPCs.
- Tertiary care practitioners should see all those at highest risk (brain, pelvic, bone tumour and transplant survivors) for hypothalampituitary hormone dysfunction, fertility counselling, cardiac and cognitive assessments and psychological support. Clear end-of-treatment summaries with information regarding long-term surveillance needs and likely consequences are required. Implicit in the latter are the increased resources needed for such age-appropriate tertiary assessment and rehabilitation services.

CONTROVERSIES AND UNADDRESSED ISSUES
The level of care provided to childhood cancer survivors remains highly variable across the UK,19 and controlled trials on the optimum frequency, duration and
quality of follow-up are still needed to determine the effectiveness of secondary prevention of, for example, congestive cardiac failure or hypocortisolaemic

**Box 2 Critical review**

- Timely update limited by absence of high-quality evidence for the cost effectiveness of the recommended lifelong three-tiered follow-up framework. Evidence graded mainly C–D (none above B) consisting largely of uncontrolled qualitative studies of patient/family satisfaction, not morbidity or mortality.21
- Inherent bias in Guideline Development Group (GDG) composition—no renal, respiratory or neurology/neuropsychology representatives with consequent omissions of important treatment-related renal, neurological and pulmonary toxicities (detailed in the UK CCGS Best Practice Statement).
- The Human Fertilisation and Embryology Act (2008)22 governing storage and use of haploid gametes and embryos is not mentioned. It mandates personal (not proxy) consent, even in children; hence an intellectual (‘Gillick’) competency assessment is required. Blood-borne virus (HIV, hepatitis B & C) testing prior to storage and written consent regarding use after death is also necessary.
- The endocrine and cognitive outcomes sections have not been updated (cited references are over 15 years old). As a result:
  - The cited data on pituitary craniopharyngiomas and hypothalamic obesity have been superseded by prospective outcome studies,23 retrospective reviews24 and guidelines,25 not identified by the GDG search strategy.
  - The recommendation that all cranially irradiated patients receive annual cognitive assessments has never been achieved even in the context of a prospective trial.15
  - The perception that cranial irradiation per se causes eventual life-threatening pituitary deficits (eg, adrenocorticotropic hormone deficiency deficiency) persists from 1987 data on adult pituitary tumours; newer evidence suggests pituitary dysfunction is confined to GH deficiency and precarious puberty except in the presence of a suprasellar tumour, which is most likely causative.26
  - Given the risk of radiation-associated subsequent primary cancers (1% lifetime risk of thyroid cancer), the carcinogenicity of nuclear fallout and an elevated thyroid-stimulating hormone (TSH)27 and the long-term cardiovascular mortality risk of subclinical hypothyroidism,28 few clinicians would overlook screening for and treating compensated hypothyroidism (raised TSH, normal free T₄) after neck irradiation.

**FURTHER RESOURCES**

- Scottish Intercollegiate Guidelines Network (SIGN) 132: Long-term follow-up of survivors of childhood cancer http://www.sign.ac.uk/pdf/sign132.pdf
- UK Children’s Cancer Study Group (UKCCSG) Best Practice Statement: Therapy-Based Long-Term Follow-Up (2nd ed.) http://www.cclg.org.uk/dynamic_files/LTFU-full.pdf
- National Cancer Survivorship Initiative (NCSI) website http://www.ncsi.org.uk/
- Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer (PanCare) http://www.pancare.eu/en/
- British Fertility Society (BFS) Consultation Paper on Fertility in Childhood Cancer http://www.britishfertilitysociety.org.uk/practicepolicy/documents/fccpaper.pdf

**Acknowledgements** We would like to thank SIGN for their kind permission in the use of table 2 and box 1 for this review.

**Contributors** H-WG wrote the initial manuscript draft, and HAS provided significant editions and useful expert opinion.

**Competing interests** None.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**

1 Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005;23:3742–51.
2 Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2009, England (MB1 40). London: Office for National Statistics, 2011.
3 Stiller CA. Childhood cancer in Britain: incidence, survival, mortality. Oxford: Oxford University Press, 2007.
4 Skinner R, Wallace WH, Levitt G. Long-term follow-up of children treated for cancer: why is it necessary, by whom, where and how? Arch Dis Child 2007;92:257–60.
5 Offinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572–82.
6 Department of Health, Macmillan Cancer Support, NHS Improvement. Living with and beyond cancer: taking action to improve outcomes. London: National Cancer Survivorship Initiative (NCSI), Department of Health, 2013.
7 Wallace WH, Blacklay A, Eiser C, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ 2001;323:271–4.
8 Scottish Intercollegiate Guidelines Network (SIGN). *Long term follow up of survivors of childhood cancer*. Edinburgh: SIGN, 2013. (SIGN publication no. 132).

9 Skinner R, Wallace WHB, Levitt GA. eds. *Therapy based long-term follow-up*. 2nd edn. UK Children’s Cancer Study Group (UK CCSG) Late Effects Group, 2005.

10 Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. *JAMA* 2011;305:2311–19.

11 Multidisciplinary Working Party convened by the British Fertility Society. A strategy for fertility services for survivors of childhood cancer. *Hum Fertil (Camb)* 2003;6:A1–A39.

12 Gan HW, Spoudeas HA. Preserving reproductive capacity in young boys with cancer. *Trends Urol Men’s Health* 2013;4:8–12.

13 Bahadur G, Ozturk O, Muneer A, et al. Semen quality before and after gonadotoxic treatment. *Hum Reprod* 2005;20:774–81.

14 Steffens M, Beauloye V, Brichard B, et al. Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). *Clin Endocrinol (Oxf)* 2008;69:819–27.

15 Bull KS, Spoudeas HA, Yadegarfar G, et al. Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). *J Clin Oncol* 2007;25:4239–45.

16 Kennedy C, Bull K, Chevignard M, et al. Quality of Survival and Growth in Children and Young Adults in the PNET4 European Controlled Trial of Hyperfractionated Versus Conventional Radiation Therapy for Standard-Risk Medulloblastoma. *Int J Radiat Oncol Biol Phys* 2014;88:292–300.

17 Sklar CA, Mertens AC, Mirthy P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. *J Clin Endocrinol Metab* 2002;87:3136–41.

18 Scottish Intercollegiate Guidelines Network (SIGN). *SIGN 50: A guideline developer’s handbook*. Edinburgh: SIGN, 2011.

19 Taylor A, Hawkins M, Griffiths A, et al. Long-term follow-up of survivors of childhood cancer in the UK. *Pediatr Blood Cancer* 2004;42:161–8.

20 Hjorth L, Kvarnstrom E. Pancreatic Childhood and Adolescent Cancer Survivor Care and Follow-up Studies. 2013. [cited 2013 2 December 2013]; http://www.pancareSurvup.eu

21 Heirs M, Suekarran S, Slack R, et al. A systematic review of models of care for the follow-up of childhood cancer survivors. *Pediatr Blood Cancer* 2013;60:351–6.

22 Human Fertilisation and Embryology Act 1990 (modified 2008). London, UK: HMSO, 2008.

23 Muller HL, Gebhardt U, Teske C, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. *Eur J Endocrinol* 2011;165:17–24.

24 Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. *Clin Endocrinol (Oxf)* 2005;62:397–409.

25 Spoudeas HA, Albanese A, Saran F, et al. Chapter One—Craniopharyngioma. In: Spoudeas HA, Harrison B. eds. *Paediatric endocrine tumours: a multidisciplinary consensus statement of best practice from a working group convened under the auspices of the British Society for Paediatric Endocrinology & Diabetes (BSPED) and United Kingdom Children’s Cancer Study Group (UKCCSG) (rare tumour working groups)*. 1st edn. Crawley, UK: Novo Nordisk Ltd., 2005:16–46.

26 Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. *Pituitary* 2009;12:40–50.

27 Jereczek-Fossa BA, Alterio D, Jassem J, et al. Radiotherapy-induced thyroid disorders. *Cancer Treat Rev* 2004;30:369–84.

28 Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA* 2010;304:1365–74.